Briefs: Emcure and Relonchem
USFDA inspection at Emcure Pharmaceuticals API facility
USFDA inspection at Emcure Pharmaceuticals API facility
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
The inspection was successfully completed
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Subscribe To Our Newsletter & Stay Updated